A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF BARICITINIB TO PRESERVE BETA CELL FUNCTION IN PARTICIPANTS NEWLY DIAGNOSED WITH TYPE 1 DIABETES AGED =1 TO <36 YEARS. (BARICADE-PRESERVE)

Intervention/treatment:
BARICITINIB (LY3009104)
Medical condition:
TYPE 1 DIABETES
Protocol code:
I4V-MC-JAJK
Control number:
303105
Status:
Recruiting
Approved:
November 26, 2025
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07222332
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
1 Year to 35 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role
CONTACT
Phone:
317-615-4559
Name
Physicians interested in becoming principal investigators please contact
Role
CONTACT
Sponsor
ELI LILLY CANADA INC

Locations

Alberta Children's Hospital
Calgary, T3B 6A8
NOT_YET_RECRUITING
Name
Carol Huang
Role
PRINCIPAL_INVESTIGATOR
Alberta Diabetes Institute
Edmonton, T6G 2E1
NOT_YET_RECRUITING
Name
Peter Senior
Role
PRINCIPAL_INVESTIGATOR
BC Diabetes Office
Vancouver, V5Y 3W2
RECRUITING
Role
CONTACT
Phone:
604-683-3734 x 1001
Name
Thomas Elliott
Role
PRINCIPAL_INVESTIGATOR
Centricity Research Ottawa LMC Endocrinology
Ottawa, K2J 0V2
RECRUITING
Role
CONTACT
Phone:
613-505-9704
Name
Nadia Malakieh
Role
PRINCIPAL_INVESTIGATOR
CHUL et Centre mère-enfant Soleil
Québec, G1V 4G2
NOT_YET_RECRUITING
Name
Martin D'Amours
Role
PRINCIPAL_INVESTIGATOR
CIUSSS- saguenay-Lac-Saint-Jean
Chicoutimi, G7H 5H6
NOT_YET_RECRUITING
Name
Raphaëlle Chrétien
Role
PRINCIPAL_INVESTIGATOR
St. Joseph's Health Care
London, N6A 4V2
NOT_YET_RECRUITING
Role
CONTACT
Phone:
519-646-6370
Name
Tamara Spaic
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?